This afternoon we watched Guardant Health rise 6.9% to a price of $53.89 per share. The Mid-Cap Medical Specialities company is now trading -12.05% below its average target price of $61.27. Analysts have set target prices ranging from $47.0 to $70.0 per share for Guardant Health, and have given the stock an average rating of buy.
The stock has an above average percentage of its shares sold short at 8.1%, and a short ratio of 4.8. Since 4.5% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 99.3% of Guardant Health's shares being owned by this investor type.
Institutions Invested in Guardant Health
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Vanguard Group Inc | 10% | 12,081,377 | $651,065,399 |
| 2025-03-31 | Blackrock Inc. | 9% | 11,173,880 | $602,160,386 |
| 2025-03-31 | Deep Track Capital, Lp | 4% | 5,443,721 | $293,362,121 |
| 2025-03-31 | Capital International Investors | 4% | 5,147,724 | $277,410,843 |
| 2025-06-30 | BAILLIE GIFFORD & CO | 4% | 4,809,786 | $259,199,364 |
| 2025-03-31 | Cadian Capital Management, LP | 4% | 4,595,087 | $247,629,235 |
| 2025-03-31 | Citadel Advisors Llc | 3% | 3,596,913 | $193,837,639 |
| 2025-03-31 | Eventide Asset Management LLC | 3% | 3,566,738 | $192,211,508 |
| 2025-03-31 | Geode Capital Management, LLC | 2% | 2,907,626 | $156,691,963 |
| 2025-06-30 | ARK Investment Management, LLC | 2% | 2,823,497 | $152,158,251 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Guardant Health.
